Special issue on Fabry disease - book 1: editorial

References

[1] Anderson W.A case of “ANGEIO-KERATOMA”.Br J Dermatol1898;10:113-7

[2] Fabry J.Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae) Arch Dermatol Syph 1898;43:187-200.

[3] de Duve C. Tissue fraction-past and present.J Cell Biol1971;50:20.

[4] Brady RO,Bradley RM,Warshaw AL.Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency.N Engl J Med1967;276:1163-7

[5] Desnick RJ,Barranger J.Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy.Ann Intern Med2003;138:338-46

[6] Schiffmann R.Investigating Fabry disease - some lessons learned.Rare Dis Orphan Drugs J2024;3:4

[7] Feriozzi S.The inflammatory pathogenetic pathways of Fabry nephropathy.Rare Dis Orphan Drugs J2024;3:11

[8] Aguiar P.Biomarkers in anderson-Fabry disease: what should we use in the clinical practice?.Rare Dis Orphan Drugs J2024;3:13

[9] West ML,Bichet DG.Fabry nephropathy: a treatable cause of chronic kidney disease.Rare Dis Orphan Drugs J2024;3:22

[10] Politei JM.Gastrointestinal involvement in Fabry disease.Rare Dis Orphan Drugs J2024;3:10

[11] Moreno-Martínez D,Reisin R.Cerebrovascular disorders and Fabry disease.Rare Dis Orphan Drugs J2024;3:9